4 completed, 2 active not recruiting, 2 terminated, 1 recruiting. 11 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Completed 4, Active not recruiting 2, Terminated 2, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow Carcinoid Tumor: new trials by email Literature Review of Carcinoid Tumor trials Research Report on Carcinoid Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms Somatostatin Analogue(s) - Neuroendocrine Neoplasm, Gastroenteropancreatic Neuroendocrine Neoplasm | Phase 3 | Recruiting | Washington University School of Medicine | 240 | 2026-11-02 | 2026-11-06 |
| Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen Paltusotine, Placebo - Carcinoid Syndrome, Carcinoid | Phase 3 | Active not recruiting | Crinetics Pharmaceuticals Inc. | 141 | 2025-11-19 | 2026-10-15 |
| Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy RYZ101, Everolimus, Sunitinib - GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor | Phase 3 | Active not recruiting | RayzeBio, Inc. | 343 | 2022-03-24 | 2026-10-05 |
| Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome Telotristat Ethyl, Lanreotide - Small Intestinal NET, Carcinoid Heart Disease | Phase 3 | Withdrawn | European Organisation for Research and Treatment of Cancer - EORTC | 2020-04-01 | 2020-02-05 | |
| An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome Lanreotide, Placebo - Carcinoid Syndrome | Phase 3 | Completed | Ipsen | 115 | 2009-05-01 | 2022-10-14 |
| Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease Pasireotide, Octreotide - Symptomatic Refractory Resistant Carcinoid Disease | Phase 3 | Completed | Novartis Pharmaceuticals | 186 | 2008-04-01 | 2013-07-30 |
| Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor Octreotide, Placebo, Everolimus - Carcinoid Tumor, Malignant Carcinoid Syndrome | Phase 3 | Completed | Novartis Pharmaceuticals | 429 | 2006-12-01 | 2014-11-21 |
| Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors Indium-111 pentetreotide - Neuroendocrine Tumors | Phase 2 / Phase 3 | Completed | Radio Isotope Therapy of America | 200 | 2005-08-01 | 2023-04-03 |
| Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion 5-Hydroxy-Tryptamine - Carcinoid Tumors, Neuroendocrine Tumors | Phase 3 | Terminated | University of Western Ontario, Canada | 8 | 2005-05-01 | 2018-04-13 |
| Comparison of Lanreotide AutogelĀ® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome lanreotide Autogel (somatostatin analogue), Sandostatin long acting release (LAR) Depot (somatostatin analogue) - Malignant Carcinoid Syndrome | Phase 3 | Terminated | Ipsen | 4 | 2004-07-01 | 2020-04-30 |
| 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors 123I-meta-iodobenzylguanidine - Pheochromocytoma, Neuroblastoma | Phase 3 | Unknown | Vancouver Coastal Health | 2011-06-15 |
Neuroendocrine Tumors (6) · Serotonin Syndrome (4) · Malignant Carcinoid Syndrome (2) · Paraganglioma (2) · Pheochromocytoma (2) · Adenoma, Islet Cell (1) · Carcinoid Heart Disease (1) · Carcinoid Tumors, Intestinal (1) · Carcinoma (1) · Carcinoma, Medullary (1) · Diarrhea (1) · Flushing (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Neoplasms (1)
Adenocarcinoma (11) · Neoplasms by Histologic Type (11) · Neoplasms, Germ Cell and Embryonal (11) · Neoplasms, Glandular and Epithelial (11) · Neoplasms, Nerve Tissue (11) · Neuroectodermal Tumors (11) · Carcinoma (10) · Neoplasms (10) · Neuroendocrine Tumors (5) · Chemically-Induced Disorders (4) · Drug-Related Side Effects and Adverse Reactions (4) · Carcinoma, Neuroendocrine (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2)
Octreotide (3) · lanreotide (3) · Everolimus (2) · Receptor-Like Protein Tyrosine Phosphatases, Class 2 (1) · Serotonin (1) · Sunitinib (1) · pasireotide (1) · telotristat ethyl (1)
Ipsen (2) · Novartis Pharmaceuticals (2) · Crinetics Pharmaceuticals Inc. (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Radio Isotope Therapy of America (1) · RayzeBio, Inc. (1) · University of Western Ontario, Canada (1) · Vancouver Coastal Health (1) · Washington University School of Medicine (1)
United States (8) · Canada (5) · Belgium (4) · Brazil (4) · France (4) · Spain (4) · Germany (3) · Italy (3) · Poland (3) · United Kingdom (3) · Argentina (2) · Czechia (2) · Netherlands (2) · Sweden (2) · Australia (1)
Angela Lamarca (1) · Daniel Worsley, MD (1) · Ebrahim Delpassand, M.D. (1) · Juan Valle (1) · Nikolaos Trikalinos, MD, MS (1) · Stan HM Van Uum, MD, PhD (1) · Ye Yuan, MD (1)
PMID 22119496, PMID 23187897, PMID 27214300, PMID 28444114, PMID 31754316, PMID 38753757
2004 (1)